The co-administration of aminoflavone and histone deacetylase inhibitors can exert an anti-tumor effect on MSL subtypes due to the ability of histone deacetylase inhibitors to sensitize MSL to aminoflavone through improving the reactivity of the aryl hydrocarbon receptor (AhR) [11,34]. Here, AHR is linked to neoplasm.